Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.53 |
| ▸ | BRD2 | P25440 | 3/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14196935 | 0.82 | BRD4 (0.61) | BRD4BRD2CREBBPNAAAMLYCD | |
| SCHEMBL8300240 | 0.74 | BRD4 (0.70) | BRD4BRD2CREBBPMLYCDBRD3 | |
| SCHEMBL5554003 | 0.74 | BRD4 (0.47) | BRD4BRD2CREBBPNAAAMLYCD | |
| SCHEMBL1772573 | 0.71 | BRD4 (0.66) | BRD4BRD2CREBBPMLYCDLMNA | |
| SCHEMBL16404607 | 0.71 | BRD4 (0.66) | BRD4BRD2MLYCDGPR55LMNA | |
| SCHEMBL12362813 | 0.71 | BRD4 (0.66) | BRD4BRD2CREBBPMLYCDERN1 | |
| SCHEMBL14678367 | 0.71 | BRD4 (0.66) | BRD4BRD2CREBBPMLYCDLMNA | |
| SCHEMBL3885694 | 0.71 | BRD4 (0.66) | BRD4BRD2CREBBPMLYCDBRD3 | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.70 | BRD4 (1.00) | BRD4BRD2CREBBPMLYCD | |
| Hydrochloric Acid SCHEMBL23174957 | 0.69 | BRD4 (0.63) | BRD4BRD2CREBBPMLYCDERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | disclosed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
| US-6875816-B2 | Catalyzing the addition polymerization in the presence of a high molecular weight catalyst and a low molecular weight catalyst | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-0874860-B1 | SUBSTITUTED INDENYL CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | DOW CHEMICAL CO (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6420507-B1 | COORDINATION CATALYSTS FOR POLYMERS | THE DOW CHEMICAL COMPANY | 2002-07-16 | — | — | US | disclosed |
| EP-0910593-B1 | ELASTOMERS AND PROCESS FOR THEIR MANUFACTURE | DOW CHEMICAL CO (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0857180-B1 | READILY SUPPORTABLE METAL COMPLEXES | DOW CHEMICAL CO (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0910593-A1 | ELASTOMERS AND PROCESS FOR THEIR MANUFACTURE | THE DOW CHEMICAL COMPANY (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998002471-A1 | ELASTOMERS AND PROCESS FOR THEIR MANUFACTURE | THE DOW CHEMICAL COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | BRD4 1705/4885BRD2 2522/4885CREBBP 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.